Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises
Rhea-AI Summary
Anteris Technologies (NASDAQ: AVR) announced completion of a $90 million strategic investment from Medtronic, closing immediately after an underwritten common stock offering for a combined $320 million in gross proceeds on Jan 22, 2026. The capital is intended to fund the global pivotal PARADIGM trial and advance commercialization of the DurAVR® Transcatheter Heart Valve (THV). Wells Fargo Securities served as sole placement agent for the Medtronic investment. Management described the funding as validation of the program and said the investment could expand into additional strategic collaboration areas.
Positive
- $320M gross proceeds raised to fund programs
- $90M strategic investment from Medtronic validates technology
- Funding dedicated to the global PARADIGM trial
- Supports advancement toward global commercialization of DurAVR THV
Negative
- Terms and scope of any future Medtronic collaboration remain unspecified
News Market Reaction – AVR
In the Jan 23 session, AVR declined 1.67%, reflecting a mild negative market reaction. Argus tracked a peak move of +10.3% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. Trading volume was exceptionally heavy at 13.1x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 20 | Offering priced | Positive | +12.5% | Pricing of $200M public offering tied to PARADIGM trial funding. |
| Jan 20 | Offering proposed | Positive | +12.5% | Proposed $200M offering plus up to $90M Medtronic investment. |
| Nov 17 | Clinical data update | Positive | -3.3% | 30-day outcomes for 100 DurAVR THV patients with strong performance metrics. |
| Nov 12 | Earnings and update | Negative | -2.6% | Q3 2025 cash burn, low cash balance and continued development-stage spend. |
| Nov 03 | FDA trial approval | Positive | -3.1% | FDA IDE approval to initiate global PARADIGM pivotal trial. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Capital-raising tied to PARADIGM and Medtronic has previously coincided with strong positive moves, while clinical and regulatory wins have at times seen muted or negative reactions.
Over the last few months, Anteris advanced its DurAVR® THV program with key regulatory and clinical milestones. FDA approval for the PARADIGM pivotal trial on Nov 3, 2025 and strong 100‑patient data later in Nov 2025 were followed by Q3 results highlighting cash burn and limited cash (about $9.1M). In Jan 2026, the company pivoted to balance-sheet strengthening, announcing and then pricing a $200M public offering plus up to $90M from Medtronic. Today’s announcement confirms completion of the $90M Medtronic investment and combined $320M gross proceeds, reinforcing funding for the global PARADIGM trial and commercialization plans.
Key Terms
tavr medical
transcatheter heart valve medical
hemodynamics medical
aortic stenosis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced today it has completed a
Anteris and Medtronic are aligned around the belief that reshaping the Transcatheter Aortic Valve Replacement (TAVR) market requires advancing clinical science and valve design while maintaining rigorous standards for durability, hemodynamics, and long‑term patient outcomes.
“This strategic investment, along with our underwritten offering of common stock, represent an important milestone for our company. It also provides strong validation of our program from the capital markets and a major strategic innovator,” said Wayne Paterson, Anteris Vice Chairman and CEO. “The investment is one aspect of a collaboration that may expand into other strategic areas in the future. Anteris has developed a clinically important, evidence-supported product designed to improve the lives of patients with aortic stenosis as we advance toward regulatory approval.”
“The Board is excited to welcome Medtronic to its stockholder community,” said John Seaberg, Chairman of the Anteris Board. “This investment aligns two organizations in their commitment to advancing valve science in a way that is disciplined and focused on long‑term patient benefit.”
“Medtronic is a pioneer in TAVR innovation and evidence,” said Jorie Soskin, Vice President and General Manager of the Structural Heart business in Medtronic’s Cardiovascular portfolio. “Our investment in differentiated innovation like the DurAVR® THV technology — which has the potential to offer improved valve performance in a balloon-expandable platform — is core to our commitment to define and drive the future of TAVR, meeting the needs of more aortic stenosis patients and heart teams with a comprehensive portfolio."
The Medtronic investment and the underwritten public offering of common stock position Anteris to continue to execute the global PARADIGM Trial and to continue investing in research that can transform the treatment of aortic stenosis. Wells Fargo Securities acted as sole placement agent in connection with the Medtronic investment.
About the PARADIGM Trial
The PARADIGM Trial is a prospective randomized controlled trial (RCT) which will evaluate the safety and effectiveness of the DurAVR® THV compared to commercially available transcatheter aortic valve replacements (TAVRs).
This head-to-head study will enroll approximately 1000 patients in the ‘All Comers Randomized Cohort' with 1:1 randomization of patients who will receive either the DurAVR® THV or TAVR using commercially available and approved THVs. The PARADIGM Trial will assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke and cardiovascular hospitalization at one year post procedure.
The PARADIGM Trial has commenced recruitment with the first patients enrolled and implanted during the fourth quarter of 2025.
For further information, please refer to ClinicalTrials.gov (ClinicaTrials.gov ID NCT07194265). The planned expansion across other geographies includes additional cohorts.
About Anteris
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
Anteris' lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.
Forward-Looking Statements
This announcement contains forward-looking statements, including statements in the quotations contained herein and regarding the use of proceeds from the Private Placement and the underwritten public offering, future collaboration between the company, the PARADIGM Trial, the potential for approval of DurAVR® THV and its ability to improve the lives of patients with aortic stenosis, and the testing of the DurAVR® THV technology. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "budget," "target," "aim," "strategy," "plan," "guidance," "outlook," "may," "should," "could," "will," "would," "will be," "will continue," "will likely result" and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under "Risk Factors" in Anteris' Annual Report on Form 10-K for the fiscal period ended December 31, 2024 and Quarterly Report on Form 10-Q for the period ended September 30, 2025, each of which was filed with the SEC and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.
For more information:
| Investor Relations | Investor Relations (US) | |
| investor@anteristech.com | mchatterjee@bplifescience.com | |
| Debbie Ormsby | Malini Chatterjee, Ph.D. | |
| Anteris Technologies Global Corp. | Blueprint Life Science Group | |
| +61 1300 550 310 | +61 7 3152 3200 | +1 917 330 4269 |
| Website | www.anteristech.com | |
| X | @AnterisTech | |
| https://www.linkedin.com/company/anteristech |
